CLRBZ - Cellectar Biosciences, Inc. - S

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.1200
-0.0250 (-17.24%)
At close: 9:36AM EST
Stock chart is not supported by your current browser
Previous Close0.1450
Open0.1200
Bid0.00 x 1000
Ask0.00 x 900
Day's Range0.1200 - 0.1200
52 Week Range0.1200 - 0.1200
Volume1,100
Avg. VolumeN/A
Market CapN/A
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • GlobeNewswire6 days ago

    Cellectar Granted Japanese Patent for CLR 131

    Cellectar Biosciences, Inc. (CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted treatments for cancer, announces that the Japan Patent Office has granted the patent titled “Phospholipid Analogs as Diapeutic Agents and Methods of Use Thereof” with application number 2016135920.  The patent provides composition of matter and use protection for the company’s proprietary phospholipid ether (PLE) analogs and specifically CLR 131 in breast, brain, leukemias and a variety of other cancers.

  • GlobeNewswire13 days ago

    Cellectar Initiates Cohort 6 of Phase 1b Trial Evaluating CLR 131 in Relapsed/Refractory Multiple Myeloma

    FLORHAM PARK, N.J., Dec. 04, 2018 -- Cellectar Biosciences (Nasdaq: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and.

  • GlobeNewswirelast month

    Cellectar Reports Third Quarter 2018 Financial Results and Provides Business Update

    Cellectar Biosciences, Inc. (CLRB) (“Cellectar” or “the Company”), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today reported financial results for the three and nine months ended September 30, 2018 and provided a business update. Announced that the U.S. Food and Drug Administration has granted an exemption to the Import Alert for CLR 131 in all hematology indications, effective immediately.  The company continues to work with the appropriate division of the FDA to obtain an exemption for its pediatric program, evaluating CLR 131 in multiple childhood cancers with significant unmet medical need.

  • GlobeNewswirelast month

    Cellectar Announces FDA Grants Exemption to Import Alert for CLR 131 Hematology Studies

    Cellectar Biosciences, Inc. (CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, announces today that the U.S. Food and Drug Administration (FDA) has granted an exemption to the Import Alert placed on the Centre for Probe Development and Commercialization (CPDC), the sole supplier of the CLR 131. The exemption for CLR 131 is effective immediately for all hematology studies and, in response, Cellectar is preparing to dose patients in the second fractionated dose cohort of the Phase 1 relapsed refractory (R/R) multiple myeloma study and the Phase 2 study for R/R hematologic malignancies.

  • GlobeNewswire2 months ago

    Cellectar Announces Overall Survival Exceeding 19 Months in Phase 1b Trial with CLR 131 in Relapsed/Refractory Multiple Myeloma

    MADISON, Wis., Oct. 02, 2018 -- Cellectar Biosciences (Nasdaq: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of.

  • GlobeNewswire3 months ago

    Cellectar Biosciences to Present at the Ladenburg Thalmann 2018 Healthcare Conference

    MADISON, Wis., Sept. 27, 2018-- Cellectar Biosciences, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, ...